-
Jiangsu Provincial Food and Drug Administration issued notice of Bristol-Myers Squibb's cancellation of drug business license
Time of Update: 2021-03-27
On March 15, the Jiangsu Provincial Food and Drug Administration issued an announcement stating that, in accordance with the "Administrative Licensing Law", "Drug Administration Law", "Drug Distribution License Management Measures" and other relevant regulations, it was approved by Bristol-Myers Squibb (China) Pharmaceutical Co.
-
The first in China! Idea Di AXL Inhibitor Application for Clinical
Time of Update: 2021-03-27
The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).
-
The targeted anticancer drug Pepaxto is included in the NCCN clinical practice guidelines for multiple myeloma in the United States
Time of Update: 2021-03-27
Recently, the company announced that its targeted anticancer drug Pepaxto (melphalan flufenamide, also known as melflufen) has been included in the National Cancer Comprehensive Network (NCCN) clinical practice for multiple myeloma guide.
-
Roche withdraws PD-L1 inhibitor Tecentriq for bladder cancer indications in the U.S.
Time of Update: 2021-03-27
As of July 2018, the data detection committee of the IMvigor130 study found that newly-treated locally advanced or metastatic urothelial cancer patients who were not suitable for cisplatin chemotherapy received Tecentriq single-agent first-line treatment, and patients with low PD-L1 expression survived As a result, the FDA has restricted Tecentriq's first-line treatment of bladder cancer as a restriction on the positive expression of PD-L1.
-
Central Document: Four New Changes in the Development of Village Clinics
Time of Update: 2021-03-27
Rural revitalization cannot do without the support of rural medical and health services, and the improvement of rural doctors' medical and health services is inseparable The promotion of rural doctors' talent team is inseparable from the expansion and development of village-level medical institutions.
-
What is the production capacity of China's antibody drugs? Can the situation of key equipment and materials be broken by import?
Time of Update: 2021-03-27
In recent years, China's antibody drug commercialization production capacity has made considerable progress, but the overall production capacity is insufficient, the production capacity is scattered, the process experience is lacking, the core equipment and materials have not been localized, and the production talent echelon has not yet formed.
-
The focus of retail pharmacy inspections is here
Time of Update: 2021-03-27
Retail pharmacies, submit a self-inspection report before the end of NovemberIn accordance with the requirements of the "Plan", the supervision of drug business links will be supervised by each city bureau over the headquarters of drug retail chain enterprises, drug and medical device network sales companies, vaccine distribution companies, and disease prevention and control institutions (the Provincial Center for Disease Control and Prevention is governed by the Hefei Municipal Bureau).
-
New news about essential medicines or increase in the proportion of essential medicines used
Time of Update: 2021-03-27
Medical Network News on March 23 Up-regulation ratio Recently, a circulating document shows that Jiangxi Province has recently adjusted the requirements for the proportion of essential medicines in public medical institutions.
-
Jinling Pharmaceutical's ferrous succinate tablets obtained the consistency evaluation of the National Food and Drug Administration
Time of Update: 2021-03-27
On March 23, Jinling Pharmaceutical issued an announcement stating that the branch Jinling Pharmaceutical Factory had recently received a notice of acceptance of the consistency evaluation of ferrous succinate tablets issued by the State Food and Drug Administration.
Jinling Pharmaceutical Factory first obtained the Drug Registration Approval for this product in 2002.
-
Novo Nordisk launches clinical trials of long-acting insulin in China once a week
Time of Update: 2021-03-27
The latest announcement of the Chinese drug clinical trial registration and information disclosure platform, Novo Nordisk launched a trial in China to study the pharmacokinetic characteristics of icodec insulin in Chinese subjects with type 2 diabetes, aiming to evaluate icodec insulin injections The stay and changes in the patient’s blood over time after administration.
-
Enhua Pharmaceutical Announces Consistency Evaluation Announcement for Aripiprazole Tablets
Time of Update: 2021-03-27
On March 18, Enhua Pharmaceuticals announced that the company recently received the "Aripiprazole Tablets" approved and issued by the State Food and Drug Administration "Drug Supplementary Application Approval Notice", approving the drug to pass the quality and efficacy of generic drugs Consistency evaluation.
-
CCTV Exposure: The price of Chinese medicine has risen again
Time of Update: 2021-03-27
cn/" target="_blank"> and regulations In addition, the publication of higher standards of the new version of the Pharmacopoeia is also conducive to the development of medicinal materials e-commerce.
-
Generic Drugs | The second domestic Chenxin Pharmaceutical Teriflunomide Generic Drug Application for Production
Time of Update: 2021-03-27
In China, teriflunomide was approved by the NMPA for the treatment of relapsing MS in July 2018, and its trade name is Aubage, becoming the first oral DMT drug approved for marketing in my country.
-
Chinese medicine is frequently difficult for companies to return goods
Time of Update: 2021-03-27
Where is the way to improve the quality of traditional Chinese medicine products and avoid excessive levels of 33 pesticide residues?In recent years, the government has given great support to the development of the Chinese medicine industry, and good news continues.
-
Eli Lilly appoints Jiang Yifei as Vice President of New Diabetes Products Division
Time of Update: 2021-03-27
On March 17, Eli Lilly officially announced that Chen Jun, the current Vice President of Eli Lilly’s China Diabetes Products Division, will leave Eli Lilly for personal reasons to seek external career development opportunities.
-
Market | Rising stars are rising, the CDK4/6 inhibitor market is getting bigger and bigger
Time of Update: 2021-03-27
However, the latest overall survival (OS) of the Phase III MONALEESA-7 study of Kisqali combined with endocrine therapy for breast cancer is close to 5 years (58.
However, Ibrance combined with endocrine therapy in the treatment of HR+/HER2-early breast cancer in two phase III clinical studies, PALLAS and PENELOPE-B, suffered Waterloo.
-
Avitinib is out? Vometinib may become the second domestic third-generation EGFR-TKI
Time of Update: 2021-03-27
Avitinib, who was expected to win the title of "the first domestically produced third-generation EGFR-TKI", was overtaken by Amitinib and missed the first one.
It is still unknown who will become the second domestically produced third-generation EGFR-TKI on the market.
-
The first Claudin 18.2/PD-L1 double antibody was approved for clinical use
Time of Update: 2021-03-27
Q-1802 is a bispecific antibody that is independently developed by Qiyu Biologics using its antibody engineering technology platform and has independent intellectual property rights that can simultaneously target PD-L1 and Claudin 18.
2/PD-L1 bispecific antibody that passed the US FDA IND.
-
Vertex begins Phase 1/2 clinical trial of VX-880 experimental treatment
Time of Update: 2021-03-27
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes
-
Authorization to introduce the dilemma again! The product has been approved for listing but was broken up by US$20 million
Time of Update: 2021-03-27
The rights that Beihai Kangcheng acquired at the time was an exclusive license agreement for the development and commercialization of lenatinib in mainland China, Taiwan, Hong Kong and Macau.
